Fabio A.B. Schutz

10.4k total citations · 1 hit paper
46 papers, 2.9k citations indexed

About

Fabio A.B. Schutz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Fabio A.B. Schutz has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Fabio A.B. Schutz's work include Renal cell carcinoma treatment (13 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Cancer Treatment and Pharmacology (8 papers). Fabio A.B. Schutz is often cited by papers focused on Renal cell carcinoma treatment (13 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Cancer Treatment and Pharmacology (8 papers). Fabio A.B. Schutz collaborates with scholars based in United States, Brazil and Spain. Fabio A.B. Schutz's co-authors include Toni K. Choueiri, Youjin Je, Joaquim Bellmunt, Jonathan E. Rosenberg, Paul L. Nguyen, Cora N. Sternberg, Georges Azzi, Guru Sonpavde, Guillermo de Velasco and Raphael Brandão Moreira and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Fabio A.B. Schutz

44 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

2017 369 citations Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fabio A.B. Schutz United States	21	1.4k	1.2k	638	592	533	46	2.9k
Yang Yao China	29	1.2k 0.8×	1.1k 0.9×	694 1.1×	301 0.5×	333 0.6×	125	2.4k
Wei‐Xiang Qi China	24	1.1k 0.8×	940 0.8×	426 0.7×	310 0.5×	391 0.7×	109	2.1k
Federica Grosso Italy	33	1.8k 1.3×	3.0k 2.6×	642 1.0×	621 1.0×	535 1.0×	158	4.4k
Xiaolei Zhu China	14	830 0.6×	678 0.6×	604 0.9×	625 1.1×	156 0.3×	35	2.1k
Shenhong Wu United States	35	2.9k 2.1×	1.7k 1.4×	1.4k 2.3×	842 1.4×	424 0.8×	96	5.5k
Stéphane Éderhy France	27	1.3k 0.9×	525 0.5×	449 0.7×	1.4k 2.3×	332 0.6×	116	3.0k
Jean‐Emmanuel Kurtz France	28	891 0.6×	1.1k 1.0×	420 0.7×	139 0.2×	364 0.7×	113	2.6k
Matthew Guo United States	22	1.5k 1.0×	2.2k 1.9×	413 0.6×	293 0.5×	1.7k 3.1×	45	4.6k
Denise K. Reinke United States	22	1.2k 0.8×	1.7k 1.4×	346 0.5×	413 0.7×	231 0.4×	54	2.8k
Michele Aieta Italy	24	1.2k 0.8×	997 0.9×	638 1.0×	152 0.3×	315 0.6×	116	2.3k

Countries citing papers authored by Fabio A.B. Schutz

Since Specialization

Citations

This map shows the geographic impact of Fabio A.B. Schutz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio A.B. Schutz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio A.B. Schutz more than expected).

Fields of papers citing papers by Fabio A.B. Schutz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio A.B. Schutz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio A.B. Schutz. The network helps show where Fabio A.B. Schutz may publish in the future.

Co-authorship network of co-authors of Fabio A.B. Schutz

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio A.B. Schutz. A scholar is included among the top collaborators of Fabio A.B. Schutz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio A.B. Schutz. Fabio A.B. Schutz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kopp, Ray Manneh, Fabio A.B. Schutz, Fabio Kater, et al.. (2024). Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma. JCO Global Oncology. 10(10). e2300244–e2300244.

Dent, R., Fabrice André, Anthony Gonçalvès, et al.. (2024). 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). ESMO Open. 9. 103202–103202. 3 indexed citations

Soares, Andrey, Fabio A.B. Schutz, Diogo Assed Bastos, Denis L. Jardim, & Fernando Sabino Marques Monteiro. (2020). Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic. PubMed. 34(3409). 370–373. 1 indexed citations

Monteiro, Fernando Sabino Marques, Andrey Soares, Márcio Debiasi, et al.. (2020). First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. Clinical Genitourinary Cancer. 18(4). 244–251.e4. 19 indexed citations

Iacovelli, Roberto, Chiara Ciccarese, Fabio A.B. Schutz, Giampaolo Tortora, & Gloria Velasco. (2020). Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. Urologic Oncology Seminars and Original Investigations. 38(10). 798.e17–798.e24. 8 indexed citations

Carril-Ajuria, Lucía, et al.. (2019). Double Immune Checkpoint Blockade in Renal Cell Carcinoma. 3(3). 163–170. 1 indexed citations

Wroclawski, Marcelo Langer, et al.. (2019). Alternative Therapies to Bacillus Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations. Journal of Global Oncology. 5(5). 1–9. 11 indexed citations

Werutsky, Gustavo, Fernando Cotait Maluf, Eduardo Cronemberger, et al.. (2019). The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 19(1). 487–487. 10 indexed citations

Velasco, Guillermo de, Youjin Je, Dominick Bossé, et al.. (2017). Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research. 5(4). 312–318. 369 indexed citations breakdown →

10.

Duran, İbrahim, Fabio A.B. Schutz, Stefanie Hamacher, et al.. (2017). The functional muscle-bone unit in children with cerebral palsy. Osteoporosis International. 28(7). 2081–2093. 10 indexed citations

11.

Moreira, Raphael Brandão, Márcio Debiasi, Edoardo Francini, et al.. (2017). Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 8(48). 84572–84578. 69 indexed citations

12.

Sonpavde, Guru, Youjin Je, Fabio A.B. Schutz, et al.. (2013). Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology. 87(1). 80–89. 50 indexed citations

13.

Schutz, Fabio A.B., Wanling Xie, Frede Donskov, et al.. (2013). The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology. 65(4). 723–730. 64 indexed citations

14.

Sonpavde, Guru, Joaquim Bellmunt, Fabio A.B. Schutz, & Toni K. Choueiri. (2012). The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports. 14(4). 295–306. 32 indexed citations

15.

Nguyen, Phuong, Youjin Je, Fabio A.B. Schutz, et al.. (2011). Meta-analysis of the Impact of Androgen Deprivation Therapy on Cardiovascular Death in Patients with Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 81(2). S6–S6. 3 indexed citations

16.

Schutz, Fabio A.B., Joaquim Bellmunt, Jonathan E. Rosenberg, & Toni K. Choueiri. (2011). Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opinion on Drug Safety. 10(4). 645–653. 23 indexed citations

17.

Schutz, Fabio A.B., Youjin Je, Georges Azzi, Paul L. Nguyen, & Toni K. Choueiri. (2010). Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology. 22(6). 1404–1412. 113 indexed citations

18.

Schutz, Fabio A.B., Toni K. Choueiri, & Cora N. Sternberg. (2010). Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology. 77(3). 163–171. 147 indexed citations

19.

Choueiri, Toni K., Fabio A.B. Schutz, Youjin Je, Jonathan E. Rosenberg, & Joaquim Bellmunt. (2010). Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Journal of Clinical Oncology. 28(13). 2280–2285. 337 indexed citations

20.

Je, Youjin, Fabio A.B. Schutz, & Toni K. Choueiri. (2009). Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. The Lancet Oncology. 10(10). 967–974. 220 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact